tradingkey.logo

Precigen Inc

PGEN
查看详细走势图
4.290USD
+0.050+1.18%
收盘 02/06, 16:00美东报价延迟15分钟
1.52B总市值
亏损市盈率 TTM

Precigen Inc

4.290
+0.050+1.18%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+1.18%

5天

-4.45%

1月

-11.55%

6月

+128.19%

今年开始到现在

+2.63%

1年

+152.35%

查看详细走势图

TradingKey Precigen Inc股票评分

单位: USD 更新时间: 2026-02-06

操作建议

Precigen Inc当前公司基本面数据相对稳定,最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理,在药品行业排名93/159位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价8.50。中期看,股价处于平稳状态。近一个月,市场表现较差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Precigen Inc评分

相关信息

行业排名
93 / 159
全市场排名
251 / 4521
所属行业
药品

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Precigen Inc亮点

亮点风险
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
业绩增长期
公司处于发展阶段,最新年度总收入3.92M美元
估值合理
公司最新PE估值-3.03,处于3年历史合理位
机构加仓
最新机构持股238.99M股,环比增加7.80%
PRFDX持仓
明星投资者PRFDX持仓,最新持仓市值14.54K
活跃度增加
近期活跃度增加,过去20天平均换手率5.55

分析师目标

根据 3 位分析师
买入
评级
8.500
目标均价
+86.40%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Precigen Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Precigen Inc简介

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
公司代码PGEN
公司Precigen Inc
CEOSabzevari (Helen)
网址https://precigen.com/
KeyAI